Skip to main content
$17.54 -$0.98 (-5.3%)

04:00 PM EST on 12/03/21

MeiraGTx Holdings plc (NASDAQ:MGTX)

CAPS Rating: No stars

Current Price $17.54 Mkt Cap $823.2M
Open $18.72 P/E Ratio 0.00
Prev. Close $17.54 Div. (Yield) $0.00 (0.0%)
Daily Range $17.32 - $18.72 Volume 161,482
52-Wk Range $11.60 - $23.15 Avg. Daily Vol. 463,204

Caps

How do you think NASDAQ:MGTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

6 Outperform
1 Underperform
 

All-Star Players

1 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:MGTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

sayyar (< 20)
Submitted February 13, 2020

Half the Pipeline validated and paid for J&J with a sweetheart deal (upfront payment, funding development costs, and giving them 20% backend of profits). They are the 3rd largest shareholder. They own a manufacturing facility. And a starting a second… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:MGTX VS S&P 500 (SPY)

NASDAQ:MGTX Summary

Fools bullish on NASDAQ:MGTX are also bullish on:

Fools bearish on NASDAQ:MGTX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MGTX.

Recs

0
Member Avatar cmrk3 (73.94) Submitted: 10/16/2021 10:45:39 AM : Outperform Start Price: $17.72 NASDAQ:MGTX Score: -2.95

MeiraGTx Holdings got a very favorable article in Barrons, Oct 16 2021. It says they have a technology that could revolutionize genetic medicine by regulating the artificial genes that gene-transfer therapies place in patients genes. The company's market capitalization is currently only 600 million dollars. They start human trials next year. Their technology is supposed to give the ability to turn any transferred gene from on to off. It does this through "riboswitches". They have acquired patents but have not published any of their research in science journals. Currently there is a gene transferring drug to cure spinal muscular dystrophy. It is the world's most expensive drug costing 2.1 million dollars for a one time dose. Meira's technology would be a lot cheaper. J & J owns 7% of this company, which is currently unprofitable.

Recs

1
Member Avatar sayyar (< 20) Submitted: 2/13/2020 5:35:22 PM : Outperform Start Price: $20.48 NASDAQ:MGTX Score: -48.24

Half the Pipeline validated and paid for J&J with a sweetheart deal (upfront payment, funding development costs, and giving them 20% backend of profits). They are the 3rd largest shareholder.

They own a manufacturing facility. And a starting a second one.

Their gene regulation technology is unique.

Leaderboard

Find the members with the highest scoring picks in MGTX.

Score Leader

mrjimijamz

mrjimijamz (23.34) Score: +22.65

The Score Leader is the player with the highest score across all their picks in MGTX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
cmrk3 73.94 10/18/2021 Outperform 3M $17.72 -1.58% +1.37% -2.95 1 Comment
TheGreatSatan 99.77 1/25/2019 Underperform 5Y $9.91 +75.98% +69.44% -6.54 0 Comment
TheTork 63.42 10/21/2021 Outperform 3W $21.00 -16.95% -0.38% -16.57 0 Comment
ChanceClub 48.81 6/4/2020 Outperform 5Y $13.95 +25.02% +44.70% -19.69 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. TMFSaintCroix 99.51 3/24/2020 Outperform 5Y $10.41 +67.53% +89.90% -22.37 0 Comment
efarev 32.53 10/1/2018 Outperform 5Y $13.79 +26.47% +54.07% -27.60 0 Comment
sayyar < 20 2/14/2020 Outperform 5Y $20.48 -14.84% +33.40% -48.24 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MGTX.